Literature DB >> 12388657

Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice.

Daniel C Broom1, Joshua F Nitsche, John E Pintar, Kenner C Rice, James H Woods, John R Traynor.   

Abstract

Delta-opioid receptor-selective agonists produce antinociception and convulsions in several species, including mice. This article examines two hypotheses in mice: 1) that antinociception and convulsive activity are mediated through the same type of delta-receptor and 2) that greater delta-agonist efficacy is required for antinociception than for convulsive activity. Delta-mediated antinociception was evaluated in the acetic acid-induced abdominal constriction assay, which involves a low-intensity noxious stimulus; convulsive activity was indicated as a mild tonic-clonic convulsive episode followed by a period of catalepsy. In delta-opioid receptor knockout mice [DOR-1(-/-)], the nonpeptidic delta-agonists (+/-)-4-[(R*)-[(2S*,5R*)-2,5-dimethyl-4-(2-propenyl)-1- piperazinyl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide hydrochloride (BW373U86) and (+)-4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N, N-diethylbenzamide (SNC80) failed to produce convulsive behavior demonstrating the absolute involvement of DOR-1 in this effect. In NIH Swiss mice expressing delta-opioid receptors, BW373U86 produced both antinociception and convulsive activity. These effects were antagonized by the putative delta(1)-receptor-selective antagonist 7-benzylidenenaltrexone and the putative delta(2)-receptor-selective antagonist naltriben. Tolerance developed to both the convulsive and antinociceptive effects of BW373U86. Tolerance to the convulsive, but not the antinociceptive, effects of BW373U86 was largely prevented when the antagonist naltrindole was given 20 min after each dose of the agonist in a 3-day treatment paradigm. The convulsive action of BW373U86 was also less sensitive than the antinociceptive action to treatment with the irreversible delta-antagonist naltrindole isothiocyanate. Collectively, these data suggest that the convulsive and antinociceptive activities of delta-agonists are mediated through the same receptor but that the receptor reserve for delta-mediated convulsive activity is greater than for delta-mediated antinociceptive activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388657     DOI: 10.1124/jpet.102.036525

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the δ-Opioid Receptor.

Authors:  Arnaud Proteau-Gagné; Véronique Bournival; Kristina Rochon; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2010-09-17       Impact factor: 4.418

Review 3.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

4.  Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys.

Authors:  Ingela Danielsson; Maciej Gasior; Glenn W Stevenson; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2006-11-15       Impact factor: 3.533

Review 5.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

6.  Docking studies suggest ligand-specific delta-opioid receptor conformations.

Authors:  Vuk Micovic; Milovan D Ivanovic; Ljiljana Dosen-Micovic
Journal:  J Mol Model       Date:  2008-12-04       Impact factor: 1.810

7.  Comparison of peptidic and nonpeptidic delta-opioid agonists on guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding in brain slices from Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Nicholas P Walker; John E Folk; Kenner C Rice; Philip S Portoghese; James H Woods; John R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2004-12-01       Impact factor: 4.030

8.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

9.  Pharmacological Properties of δ-Opioid Receptor-Mediated Behaviors: Agonist Efficacy and Receptor Reserve.

Authors:  Isaac J Dripps; Ruizhuo Chen; Amanda M Shafer; Kathryn E Livingston; Alexander Disney; Stephen M Husbands; John R Traynor; Kenner C Rice; Emily M Jutkiewicz
Journal:  J Pharmacol Exp Ther       Date:  2020-05-28       Impact factor: 4.030

10.  The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.

Authors:  Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz
Journal:  Psychopharmacology (Berl)       Date:  2016-09-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.